ResMed (RMD) Tops Q2 EPS by 22c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Price: $240.51 +5.91%
Financial Fact:
Cost of sales: 196.27M
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
Cost of sales: 196.27M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q2 EPS of $1.00, $0.22 better than the analyst estimate of $0.78. Revenue for the quarter came in at $601 million versus the consensus estimate of $580.32 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Phibro Animal Health (PAHC) Tops Q1 EPS by 2c; Offers Guidance
- Black Hills Corp. (BKH) Tops Q3 EPS by 6c, Misses on Revenue; Offers FY26 EPS Guidance
- Inter Parfums (IPAR) Tops Q3 EPS by 33c ; Offers Guidance
Create E-mail Alert Related Categories
Corporate News, Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
